Market Intelligence, Clinical Progress, and High-Purity Reagents for Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Multiple Endocrine Neoplasia Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for MEN1 (Menin) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MEN1 Full-Length Recombinant Protein (WT & Mutant Panel) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native folding and PTMs. |
View MEN1 Products |
| Mutant Panel | MEN1 Cancer-Associated Mutants (e.g., M327I, R395W, Q34X, R527X) For selectivity screening vs. wild-type tumor suppressor; key for drug resistance studies. |
View MEN1 Products |
| Interaction Partner | KMT2A/MLL1 Binding Domain Protein For PPI assays and competition studies. |
View KMT2A Products |
| Gene Delivery | MEN1 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable cell line construction and Menin-MLL reporter assays. |
View MEN1 Products |
| Benchmark Ab | Anti-MEN1 Recombinant Antibody (Reference Clone) Sequence-verified control for Co-IP, WB, and target engagement. |
View MEN1 Products |
| Validator | MEN1 siRNA Set For knockdown verification and specificity control in KMT2A-rearranged leukemia models. |
View MEN1 Products |
| Related Target A | KMT2A (MLL1) Direct Menin binding partner; essential for oncogenic PPI disruption assays. |
View KMT2A Products |
| Related Target B | NPM1 NPM1-mutated leukemias show high sensitivity to Menin inhibitors. |
View NPM1 Products |
| Related Target C | MLLT3 (AF9) Frequent KMT2A fusion partner; required for disease-relevant co-complex studies. |
View MLLT3 Products |
| Related Target D | DOT1L Downstream methyltransferase; synthetic lethal pathway for combination strategies. |
View DOT1L Products |
| Related Target E | CDK9 Synergistic target with Menin inhibitors in AML proliferation. |
View CDK9 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Menin-MLL PPI Disruption Assay (TR-FRET/AlphaScreen) | High-purity (>95%) WT MEN1 recombinant protein + KMT2A binding domain peptides optimized for FP/TR-FRET. |
| Drug Resistance Counter-Screening (Mutant Profiling) | Clinical mutant proteins (e.g., M327I, R395W) strictly sequence-verified by mass spectrometry; WT vs mutant shift assay support. |
| Cellular Target Engagement in KMT2A-r Models | MEN1 Lentivirus for stable expression in reporter and leukemia cell lines, preserving native folding. |
| Off-Target Liability vs. KMT2B & Other Homologs | KMT2A/KMT2B Win-motif peptide panels for orthogonal selectivity assays; siRNA included for specificity validation. |
| Lack of Validated Positive Controls | Anti-MEN1 reference antibody and control inhibitors included to establish baseline assay performance. |
| Nuclear Localization & Chromatin Binding Assays | Full-length MEN1 lentivirus enables stable cell lines retaining native PTMs; compatible with cellular thermal shift assays. |
| Ortholog Cross-Reactivity (Mouse/Rat PK/PD) | Human/Mouse/Rat MEN1 proteins available with >90% sequence homology; ideal for preclinical species translation. |
Live MEN1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MEN1-targeted therapeutics is intensifying. First-generation small-molecule Protein-Protein Interaction (PPI) inhibitors disrupting the Menin-MLL complex, such as Syndax's revumenib (now approved for KMT2A-rearranged acute leukemia) and Kura Oncology's ziftomenib (Phase 3 in NPM1-mutant AML), have demonstrated profound efficacy. The field is rapidly advancing into combination frontline regimens (e.g., with FLT3, CDK9, or BCL-2 inhibitors) and exploring next-generation modalities including covalent inhibitors (Biomea Fusion's BMF-219) and PROTAC-mediated Menin degradation to bypass scaffolding-related resistance mechanisms. Acquired resistance mutations (e.g., MEN1 somatic mutations like M327I) are driving demand for mutant protein panels, while brain-penetrant formulations are being developed for CNS leukemia involvement. Beyond hematology, Menin inhibitors are under investigation for solid tumors such as pancreatic neuroendocrine tumors (PanNETs) associated with MEN1 syndrome.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitor | Syndax, Kura Oncology, Janssen/JNJ | AML (MLL-r, NPM1-mut), ALL | High-purity WT MEN1 + KMT2A proteins for TR-FRET/AlphaScreen; mutant selectivity panels. |
| Covalent / Next-Gen Inhibitor | Biomea Fusion | Relapsed/Refractory AML | Target residence time assays requiring WT vs mutant MEN1 proteins. |
| PROTAC Degrader | Various Biotech, Academia | Refractory Leukemia, Solid Tumors (PanNETs) | Ternary complex formation assays (E3 ligase + MEN1 proteins); lentivirus for stable cell lines. |
| Combination Therapy | AbbVie, Novartis, Jazz Pharma | Frontline AML, Relapsed/Refractory AML | Pathway validation reagents (BCL2, FLT3, CDK9); stable Menin-reporter cell lines. |